1. Introduction {#s0005}
===============

Stroke is a common neurological disorder affecting the global population of 15 million; among them ∼5 million suffer from the permanent disability, and 5.5 million dies due to stroke-related factors ([@b0115]). Etiologically, ischemic stroke (IS) is supposed to be a highly complex disease influenced by genetic and environmental issues ([@b0175]). This disease has considered as a fourth commonest leading cause of death, lasts neurologic impairment, functional disability, and stroke aetiology is multifactorial and conventional forms of inheritance cannot be confirmed ([@b0085]). The verified risk factors as age, cigarette smoking, diabetes, hypertension, hyperlipidemia and detected comorbidities as HIV, sickle cell disease, cerebral malaria are progressively being encountered. Based on the availability, IS can be effected with the physical damage, psychological, social and cognitive functions ([@b0050], [@b0180]). However, in IS, the aetiology and risk factors may vary from those for myocardial infarction ([@b0165]). The genetic roles in IS have been established in numerous reports entails in twins and family models ([@b0150]). The discovering of predisposing to stroke in genetic variants could be a vital step towards the expansion of enhanced diagnostic tests for stroke. Genome-wide association studies (GWAS) has recognised merely a few confirmed loci for a small amount of the heritable risk ([@b0140]). Genetic epidemiology mainly involves with complex diseases such as stroke and frequently observed in the population-based studies. However, the disease is polygenic in origin with an involvement of multiple genes ([@b0225]). In human diseases, GWAS were used as an influential device to identify the recognised marker and helps the classifying genetic variations that contribute to common and complex diseases (Example: Stroke or Ischemic Stroke) ([@b0200]). Identification of risk through single nucleotide polymorphisms (SNPs) can be confirmed with GWAS and meta-analysis ([@b0160]). It has demonstrated various polymorphisms of different genes were strong risk locus for stroke and controversial results were adapted from global population. Many candidate genes have been studied for their potential roles in IS. However, preliminary case-control studies adopt the principal data in genetic epidemiology, and such studies are useful in originating the appropriate conclusions for genetic polymorphisms ([@b0070]). Meta-analysis studies are defined as a statistical tool, merging the case-control study results of different ethnic studies on the similar topic, and it has become the popular method for resolving discrepancies in genetic association studies ([@b0125]). Many meta-analysis studies have been carried out in stroke and concluded as positive ([@b0095], [@b0145], [@b0235], [@b0240], [@b0265]), negative ([@b0230], [@b0245]) and nominal associations ([@b0130]).

Sortilin (SORT1) gene has been identified through GWAS studies, and it appears on chromosome 1p13.3 regions ([@b0105]). *SORT1* is expressed both in neurons cum non-neuronal cells and encodes for the sorting protein that plays an important role in the uptake of lipids ([@b0035], [@b0040]). However, [@b0135]) confirmed functional variants at this locus might reside within the *SORT1* gene since the risk allele was associated with decreased *SORT1* expression, increased plasma Low density lipoprotein-cholesterol (LDL-C) concentration, and increased coronary artery disease (CAD) risk. Earlier studies also showed the significance association with CAD risk ([@b0060], [@b0065], [@b0080], [@b0120], [@b0170], [@b0185], [@b0215]). The Oxidized Low Density Lipoprotein Receptor 1 (*OLR1*) gene was identified as a cell surface endocytosis receptor for oxidised low-density lipoprotein (Ox-LDL) on vascular endothelial cells ([@b0090]). The *OLR1* gene consists of six exons and five introns, spans 7-kb, which located on chromosome 12p13.1-p12.3. The SNPs in the *OLR1* gene have been identified, including G501C transversion on exon 4, results in an amino acidic substitution from Lysine-Asparagine at position 167. The rs11053646 polymorphism in the oxidised LDL binding domain of LOX-1 causes to decrease binding and internalisation of ox-LDL7 and has been associated with hypertension, myocardial infarction and carotid atherosclerosis and importantly, G501C SNP is statistically linked to the risk of IS. The deletion in *OLR1* gene is possible while an increase in the OLR1 overexpression, plaque formation and development through the demonstration in the atherosclerosis mouse models ([@b0045], [@b0220]).

However, confirmed through GWAS and meta-analysis variants have little information with stroke and there are no genetic studies in Saudi Arabia, which is known to be obese as it is existent in the Arab region. The prevalence of obesity has been drastically increased due to western lifestyle and uncontrolled diet. The women are more effected with obesity compared with the males. This is the reason we have opted one-third of males (*n* = 69) and two-third of females (*n* = 138) in both the cases and controls. This present study in Saudi population aims to evaluate the potential association of SNPs identified through GWAS and meta-analysis studies in stroke patients.

2. Materials and methods {#s0010}
========================

2.1. Ethical concern {#s0015}
--------------------

Ethical approval grant has been sanctioned for this study from College of Applied Medical Sciences, King Saud University (CAMS 047-37/38).

2.2. Patient selection {#s0020}
----------------------

In this study, 414 Saudi subjects were selected from King Saud University Hospital in a capital city of Saudi Arabia. We have recruited 420 subjects based on the inclusion and exclusion criteria. All the subjects (*n* = 420) were the native of the Saudi population. Patients with major cardiac, renal, hepatic, skeletal disorders and cancerous diseases (*n* = 6) were excluded from this study. The patients' details such as demographic information and lipid profile parameters were included in structured proforma. Two hundred and seven healthy controls were recruiting from general Saudi population without any disorder or diseases. The patient selection details were described in our prior publications ([@b0015]). Routinely, 5 ml of peripheral blood was collected, and 3 ml of serum sample was used for biochemical analysis and remaining 2 ml of the EDTA blood was used to separate the genomic DNA.

2.3. Biochemical assessment {#s0025}
---------------------------

A serum sample was used for analyzing the lipid profile parameters such as Total cholesterol (TC), Triglycerides (TG), High-density lipoprotein-cholesterol (HDL-C) and LDL-C, measured by automated clinical chemistry analyser (KoneLab) using the commercially available kits.

2.4. Genetic analysis and quality control {#s0030}
-----------------------------------------

Genomic DNA was isolated with the commercial kit available from Norgen Biotech Corporation. The valuation for DNA samples were confirmed with NanoDrop spectrophotometer and stored in −80 °C. Two SNPs were selected based on the design of the study from GWAS (rs464218) and meta-analysis (rs11053646) studies. Primers were designed for Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) analysis and synthesised from Bioserve Biotechnologies Limited. Gene amplification was carried out with thermal PCR in a 25 µL reaction mixture ([@b0020]). The PCR products were digested for 16 h for both the variants and run on 3% agarose gel. The complete PCR-RFLP details are tabulated in [Table 1](#t0005){ref-type="table"}. The quality control was performed in both SNPs of cases and controls ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}) by determining the genotypes in total call rate and minor allele frequencies, indicating ∼10% of random samples, i.e., 30 cases and 30 control samples have been performed the DNA sequencing analysis.Fig. 1A 3% agarose gel electrophoretograms of *SORT1* digested products after *Hha*I restriction enzyme.Fig. 2Digested *OLR1* gene products run on 3% agarose gel electrophoresis with *FNU4H*I restriction enzyme.Table 1List of single nucleotide polymorphisms details involved in this study.Geners numberChr. PositionForward PrimerReverse PrimerProtein changePCREnzymeRFLP*SORT1*rs464218109313684GGTGTGCAGTGTTCTTGGAGTGGAATTCGAAGGGACCTTTTCA--233bpHhaIA-233bp; G-181/52bp*OLR1*rs1105364610160849GGCTCATTTAACTGGGAAAGCCTGTCCGTCCAAGGTCATALys-Asn243bpFNU4HIG-243bp; C-222/21bp

2.5. Statistical analysis {#s0035}
-------------------------

Clinical characteristics of incorporated subjects were expressed as Mean ± SD. Clinical data was compared between cases and controls using Student\'s t-test. Genotype and allele frequencies were calculated by gene counting method, and the chi-square (X^2^) tests were used to identify departures from Hardy-Weinberg equilibrium (HWE). The odds ratio (OR) and 95% confidence intervals (CI/CIs) were also calculated. Multinomial logistic regression analysis was also performed within the genotype analysis incorporating age, gender, and Body mass index (BMI). Analysis of variance (ANOVA) was used to compare differences between genotypes, BMI and lipid profile parameters. Yates correction was performed in cases and controls for the rs11053646 variant. A p-value \< 0.05 (two-sided) was considered to be significant. Statistical analysis was performed using the SPSS statistical package (Version 21.0, SPSS Inc., and Chicago, IL, USA).

3. Results {#s0040}
==========

3.1. Baseline features {#s0045}
----------------------

During this study process, 207 cases and 207 controls were recruited to perform the case-control study. However, the clinical details were documented in [Table 2](#t0010){ref-type="table"}. The mean age of the cases and controls were found to be 30.6 ± 4.2, and 27.1 ± 6.1 and t-test were found to be 0.001. There was no significant difference between the groups on gender, height and HDL-C parameters (p \> 0.05). However, on another side, the positive association was confirmed with weight, BMI, TC, TG and LDL-C (p \< 0.05).Table 2Demographic characteristics of selected cases and controls.S.NoCases (*n* = 207)Controls (*n* = 207)P Value1Gender (M:F)69 (33%):138 (67%)69 (33%):138 (67%)0.992Weight (kg)74.1 ± 12.368.7 ± 20.30.0013Height (cms)157.7 ± 5.2162.1 ± 8.10.124BMI (kg/m^2^)29.7 ± 4.325.7 ± 6.10.00015TC (mmol/L)5.1 ± 1.04.7 ± 1.20.0096TG (mmol/L)1.7 ± 0.91.3 ± 0.60.00017HDL-C (mmol/L)0.7 ± 0.20.8 ± 0.40.138LDL-C (mmol/L)3.7 ± 0.92.4 ± 0.70.003

3.2. Genotype association {#s0050}
-------------------------

In this study, rs464218 and rs11053646 polymorphisms were carried out between the cases and controls. Both the variants appeared in HWE in both the groups. The genotype and allele frequencies of cases and controls were tabulated in [Table 3](#t0015){ref-type="table"}. AA, AG and GG are the three genotypes were detected in the rs 464218 variant in *SORT1* gene. The genotype frequencies observed in cases are 30.4% in AA, 51.2% in AG and 18.4% in GG, where as in controls, it was found to be 41.5% in AA, 44.4% in AG and 14% in GG genotypes respectively. The genotype distribution between cases and healthy controls were significantly associated with AG genotypes, dominant model and G allele \[(AG Vs AA; OR = 1.57, 95%CI = 1.02--2.41; p = 0.03); (AG + GG vs AA; OR = 1.62, 95%CI = 1.08--2.43; p = 0.01) and (G vs A; OR = 1.38, 95%CI = 1.04--1.82; p = 0.02)\]. The positive association was also observed when we adjusted the genotype data with age, gender and BMI i.e., with AG genotypes, Dominant model and G allele \[(AG Vs AA; OR = 1.93, 95%CI = 1.19--2.65; p = 0.02); (AG + GG vs AA; OR = 1.78, 95%CI = 1.17--2.65; p = 0.03) and (G vs A; OR = 1.50, 95%CI = 1.03--2.12; p = 0.02)\]. The variant model (GG vs AA) was found to be similarly associated with AG genotype (GG Vs AA; OR = 1.78, 95%CI = 1.01--3.20; p = 0.04).Table 3Genotype and allele distributions of rs464218 and rs11053464 variants analyses and adjusted with potential confounders (N = 207).GenotypeCase (N%)Control (N%)X^2^Crude OR (95% CI)P valueOR (95% CI)[a](#tblfn1){ref-type="table-fn"}P Value*rs464218*AA63 (30.4%)86 (41.5%)ReferenceAG106 (51.2%)92 (44.4%)4.21.57 (1.02--2.41)0.031.93 (1.19--2.65)0.02GG38 (18.4%)29 (14.0%)3.81.78 (1.01--3.20)0.041.87 (1.22--3.41)0.04AG + GG Vs AA144 (69.6%)121 (58.4%)5.51.62 (1.08--2.43)0.011.78 (1.17--2.65)0.03AG Vs AA + GG106 (51.2%)92 (44.4%)1.91.31 (0.89--1.93)0.16\--GG Vs AA + AG38 (18.4%)29 (14.0%)1.41.38 (0.81--2.33)0.23\--A232 (0.56)264 (0.64)ReferenceG182 (0.44)150 (0.36)5.11.38 (1.04--1.82)0.021.50 (1.03--2.12)0.02  *rs11053646*GG177 (85.5%)191 (92.2%)ReferenceGC30 (14.5%)16 (7.8%)4.72.02 (1.06--3.83)0.022.01 (1.03--3.8)0.01CC00 (00)00 (00)0.0011.07 (0.02--54.6)0.96\*\--GC + CC Vs GG30 (14.5%)16 (7.8%)4.71.99 (1.05--3.75)0.03\*\--GC Vs GG + CC30 (14.5%)16 (7.8%)\-\-\-\--CC VS GG + CC00 (00)00 (00)\-\-\-\--G384 (0.93)398 (0.96)ReferenceC30 (0.07)16 (0.04)4.51.94 (1.04--3.62)0.032.1 (1.09--3.82)0.04[^1]

The other variant rs11053646 was carried out with similar subjects and frequencies of GG and GC genotypes were 85.5% and 14.5% in cases and 92.2% and 7.8% in controls. CC genotype was completely absent in all the subjects. In this statistical analysis, we find significant association in GC and C allele \[(GC Vs GG; OR = 2.02, 95%CI = 1.06--3.83; p = 0.02) and (C vs G; OR = 1.94, 95%CI = 1.04--3.62; p = 0.03)\]. After adjusting the Yates\' correction, the dominant model was found to be associated (GC + CC vs GG; OR = 1.99, 95%CI = 1.05--3.75; p = 0.03). In this variant also positive association was observed when adjusted with the genotype data correlated with age, gender and BMI, i.e., with GC genotypes and C allele \[(GC vs GG; OR = 2.01, 95%CI = 1.03--3.80; p = 0.01) and (C vs G; OR = 2.10, 95%CI = 1.09--3.82; p = 0.04)\].

3.3. Association of rs464218 and rs11053646 variants with combined parameters {#s0055}
-----------------------------------------------------------------------------

ANOVA analysis was carried out with the study effects of rs464218 and rs11053646 variants on the different parameters. We analysed the distribution of these variables about the various genotypes in the selected polymorphisms. BMI could not show the association with any of the genotypes in rs464218 and rs11053646 variants. Although the association was found with TG in both rs464218 (p = 0.003) and rs11053646 (p = 0.002) variants and rs11053646 variant, HDL-C was significantly associated (p = 0.04). The complete data of ANOVA analysis was documented in [Table 4](#t0020){ref-type="table"}.Table 4Correlation between BMI, lipid profile and genotypes involved in this study.Genotypes*SORT1*(rs464218)*OLR1*(rs11053646)AAAGGGP valueGGGCCCP valueN63 (30.4%)106 (51.2%)38 (18.4%)--177 (85.5%)30 (14.5%)00 (00)--BMI(kg/m^2^)29.72 ± 4.4429.15 ± 4.4230.16 ± 4.170.8929.82 ± 4.6329.68 ± 4.330.0 ± 0.00.64TC (mmol/L)5.22 ± 1.055.09 ± 1.084.94 ± 0.850.235.13 ± 0.905.10 ± 1.060.0 ± 0.00.23TG (mmol/L)1.76 ± 1.011.72 ± 1.001.37 ± 0.620.0031.52 ± 0.591.69 ± 1.000.0 ± 0.00.002HDL-C (mmol/L)0.65 ± 0.240.66 ± 0.250.69 ± 0.210.450.70 ± 0.190.66 ± 0.250.0 ± 0.00.04LDL-C (mmol/L)3.77 ± 0.883.64 ± 0.933.63 ± 0.800.543.73 ± 0.863.67 ± 0.900.0 ± 0.00.74[^2]

3.4. Gender-based association within the genotypes {#s0060}
--------------------------------------------------

Gender-based genotype association was tabulated in [Table 5](#t0025){ref-type="table"} as male and female subjects. We could not find any statistical association when compared in rs464218 polymorphism with male and female subjects in cases vs controls (p \> 0.05). However, with rs11053646 polymorphism, a positive association was observed only in the comparison between male cases vs male controls with GC genotype and C allele \[(GC vs GG; OR = 5.60, 95%CI = 1.53--20.49; p = 0.04) and (C vs G; OR = 5.08, 95%CI = 1.42--18.10; p = 0.005)\]. The dominant model also seems to be positive association after the Yates correction in male controls vs male cases \[GG + CC vs GG; OR = 4.96, 95%CI = 1.46--16.82; p = 0.005\].Table 5Association of *SORT1* and *OLR1* genotypes in Stroke male and female subjects.GenotypeCase (*n* = 69)Control (*n* = 69)OR (95% CI)P valueCase (*n* = 138)Control (*n* = 138)OR (95% CI)P valueMale SubjectsMale SubjectsFemale SubjectsFemale Subjects*rs464218*AA18 (26.1%)27 (39.1%)Reference45 (32.6%)59 (42.7%)ReferenceAG37 (53.6%)32 (46.4%)1.73 (0.81--3.71)0.1569 (50.0%)60 (43.5%)1.50 (0.89--2.53)0.12GG14 (20.3%)10 (14.5%)2.1 (0.76--5.74)0.1424 (17.4%)19 (13.8%)1.65 (0.80--3.38)0.16AG + GG Vs AA51 (73.9%)42 (60.9%)1.82 (0.88--3.75)0.193 (67.4%)79 (57.3%)1.54 (0.94--2.52)0.08A73 (0.53)86 (0.62)Reference159 (0.58)178 (0.64)ReferenceG65 (0.47)52 (0.38)1.47 (0.91--2.37)0.11117 (0.42)98 (0.36)1.33 (0.94--1.88)0.09  *rs11053646*GG55 (79.7%)66 (95.6%)Reference122 (88.4%)125 (90.6%)ReferenceGC14 (20.3%)3 (4.4%)5.6 (1.53--20.49)0.0416 (11.6%)13 (9.4%)1.26 (0.58--2.73)0.55CC00 (00)00 (00)1.19 (0.02--61.35)0.92[a](#tblfn2){ref-type="table-fn"}00 (00)00 (00)1.02 (0.02--52.03)0.99[a](#tblfn2){ref-type="table-fn"}GC + CC Vs GG14 (20.3%)3 (4.4%)4.96 (1.46--16.82)0.005[a](#tblfn2){ref-type="table-fn"}16 (11.6%)13 (9.4%)1.25 (0.58--2.68)0.56[a](#tblfn2){ref-type="table-fn"}G124 (0.90)135 (0.98)Reference260(0.94)263 (0.95)ReferenceC14 (0.10)3 (0.02)5.08 (1.42--18.10)0.00516 (0.06)13 (0.05)1.24 (0.58--2.64)0.56[^3]

4. Discussion {#s0065}
=============

The aim of the present study was to investigate the confirmed variants through GWAS and meta-analysis studies with stroke in the Saudi population. As per the literature, this will be the initial study performed in the Saudi population. The results of currents study confirm positive association in rs464218 (*SORT1*) and rs11053646 (*OLR1*) variants with allele, genotype and dominant models (p \< 0.05). In rs11053646 polymorphisms with male subjects compared between cases and controls found to be associated with dominant model heterozygote genotypes (p \< 0.05). In both the polymorphisms, genotypes were associated with triglycerides when we correlated (p \< 0.05). The prevalence of stroke is increased and confirmed as the second cause of disability as well as the fourth cause of death in the global population. However, burden with high proportion is divided in the developing countries because of larger populations. Stroke as a complex disorder is quite difficult to rule out the involvement of genetic and environmental components. The prior studies have reported the identified genetic associations with stroke and other diseases (example: coronary heart disease and atrial fibrillation). There are limited number of genetic studies have been carried out in Saudi Arabia with stroke. Although, Saudi Arabia, is known to be obese country as it is existent in the Arab region. The prevalence of obesity has been drastically increasing due to western lifestyle and free diet. The women are more affected with obesity compared with the males. This study could help the Saudi origin to design the disease marker by implementing the genetic and molecular studies by enrolling non-obese subjects. A large number of genes have been identified to be associated with the risk of genetic diseases, and among them, the genes involved in the synthesis and metabolism of serum lipids have been subject of intense research due to their clinical significance and their ability to be quantified from the serum. The prognosis of stroke mainly depends on interaction amongst the baseline characteristics ([@b0055], [@b0195]). Currently, GWAS have identified more than thousands of SNPs connected with human diseases and complex traits which have been a success in elucidating pathophysiological mechanisms underlying diseases with the genetic influence ([@b0210], [@b0260]). Familial studies have provided the relation between heritability and multifactorial diseases. Stroke is influenced by environmental factors and genetics is considered as a fourth leading cause of death in the world ([@b0205]). Genome-wide linkage, meta-analysis, candidate gene, GWAS, twin and family association studies suggested that genetic variances are responsible for the varied risk of ischemic stroke ([@b0255]).

Several studies have documented the relation between stroke and atherosclerosis ([@b0100], [@b0190]). As per the World Health Organization, stroke is defined as the clinical syndrome typified by rapidly developing signs of focal or global disturbance of cerebral functions, lasting more than 24 h or leading to death, with no apparent causes other than of vascular origin ([@b0235]). Almost all, ∼50% of the strokes are caused by atherosclerosis, defined as a type of disease in which plaques build up in the arteries. The presence of unstable atherosclerotic plaques in the carotid artery is a known etiological factor causing cerebrovascular events, such as an ischemic stroke, transient ischemic attack, or amaurosis fugax. Thus, carotid atherosclerotic plaque represents an important disease burden, as stroke is one of the leading causes of death worldwide and a major cause of long-term disability ([@b0075]). An earlier study by [@b0155]) confirmed the genetic relation association through LDLR levels act the binding of a key transcription factor and shifting the expression of the *SORT1* gene involved in intracellular protein transport. The rs464218 polymorphism in *SORT1* gene has been identified by GWAS in Europe, East Asian, Southern Asian, Middle Eastern Asian and Africa Americans populations ([@b0060], [@b0065], [@b0080], [@b0120], [@b0170], [@b0185], [@b0215]). Our current study results with rs464218 polymorphism are in association with [@b0270]) and [@b0110]) studies but differ in the genotype frequencies, and this could be due to the ethnicity. In our study, the rs11053646 polymorphism in *OLR1* gene was associated, and our results confirm the earlier meta-analysis studies, concluding as may contribute to the risk of disease susceptibility ([@b0045]). In Saudi Arabia, there are limited studies have been documented with stroke, and among them, [@b0025]) performed the molecular study with *CYPC219* genetic polymorphisms and found to be associated. [@b0030]) performed the detailed study of stroke who were effected for the first time. There are many other studies have been carried out in stroke as hospital-based and cross-sectional studies in the kingdom ([@b0005], [@b0010], [@b0250]). The current study has couple of limitations and among them (i) selection of single SNPs from each gene and (ii) missing the MRI scan. The advantage of this study was selection of pure Saudi patients. In conclusion, our results confirm the *SORT1* and *OLR1* variants were associated in the Saudi population. The current results were in the association with the prior study results documented through GWAS and meta-analysis association. However, global ethnic population studies should be performed to rule out in the human hereditary diseases in all ethnicities.
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[^1]: Odds ratio (95% CI) adjusted with Age, Gender and BMI.

[^2]: Data represented by Mean±standard deviation.

[^3]: Indicates Yates correction.
